TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: A pilot trial

Annals of Surgical Oncology

Volumn 15, Issue 4, 2008, Pages 1218-1223

  Rossi, Carlo Riccardo ^a,c   Russano, Francesco ^a   Mocellin, Simone ^a   Chiarion Sileni, Vanna ^b   Foletto, Mirto ^a   Pilati, Pierluigi ^a   Campana, Luca G ^a   Zanon, Antonio ^a   Picchi, Gian Franco ^a   Lise, Mario ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Clinica Chirurgica II   (Italy)

Author keywords

Interferon alpha (IFN ); Isolated limb perfusion; Melanoma; Tumor necrosis factor (TNF)

Indexed keywords

ALPHA2B INTERFERON; MELPHALAN; RECOMBINANT ALPHA2B INTERFERON; TASONERMIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTHROPOMETRY; BIOLOGICAL THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IN-TRANSIT MELANOMA METASTASIS; IN-TRANSIT METASTASIS; LIMB PERFUSION; LOG RANK TEST; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PILOT STUDY; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PILOT PROJECTS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40549107085     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9791-z     Document Type: Conference Paper

References (19)

1. Balch CM, Houghton A, Sober AJ, et al. Cutaneous melanoma, 4th ed. Quality Medical Publishing Corporation, St. Louis; 2003
2. Grunhagen DJ, de Wilt JH, van Geel AN, et al. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006;32:371-80.
3. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429-37.
4. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion in regional melanoma. Surg Oncol Clin North Am. 2006;15:373-84.
5. Rossi CR, Foletto M, Pilati P, et al. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol. 2002;29:400-9.
6. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6.
7. Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53.
8. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998;4:408-14.
9. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-64.
10. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15:431-9.
11. Indraccolo S, Tisato V, Tosello V, et al. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum Gene Ther. 2005;16:957-70.
12. Slaton JW, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726-34.
13. Ozawa S, Shinohara H, Kanayama HO, et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia. 2001;3:154-64.
14. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-48.
15. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol. 2004;11:173-7.
16. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-10.
17. Casara D, Rubello D, Pilati P, et al. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nucl Med Commun. 2004;25:61-6.
18. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196-201.
19. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.